Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pediatr Emerg Care ; 33(5): 344-345, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-27299295

RESUMEN

We report a case of mild cannabinoid poisoning in a preschool child, after 3-week ingestion of hemp seed oil prescribed by his pediatrician to strengthen his immune system. The patient presented neurological symptoms that disappeared after intravenous hydration. A possible mild withdrawal syndrome was reported after discharge. The main metabolite of Δ-tetrahydrocannabinol was detected in urine, and very low concentration of Δ-tetrahydrocannabinol was detected in the ingested product. This is, as far as we know, the first report of cannabinoid poisoning after medical prescription of hemp seed oil in a preschool child.


Asunto(s)
Cannabinoides/envenenamiento , Cannabis/efectos adversos , Dronabinol/orina , Aceites de Plantas/uso terapéutico , Intoxicación/diagnóstico , Semillas/efectos adversos , Síndrome de Abstinencia a Sustancias/diagnóstico , Preescolar , Citocromo P-450 CYP2C9/metabolismo , Citocromo P-450 CYP3A/metabolismo , Dronabinol/metabolismo , Humanos , Infusiones Intravenosas/métodos , Masculino , Aceites de Plantas/administración & dosificación , Aceites de Plantas/efectos adversos , Intoxicación/etiología , Intoxicación/terapia , Síndrome de Abstinencia a Sustancias/etiología , Resultado del Tratamiento
2.
J Pediatr Hematol Oncol ; 37(2): 156-7, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25493456

RESUMEN

We describe the case of an 8-year-old girl with common precursor B-cell acute lymphoblastic leukemia who presented with severe pancytopenia during maintenance therapy with methotrexate and 6-mercaptopurine. The bone marrow smear showed moderate hypocellularity and trilinear dysplastic changes consistent with a diagnosis of drug toxicity, with no evidence of lymphoblasts. Flow cytometric immunophenotyping was negative for leukemic cells. Blood cell counts normalized after treatment with folinic acid. Maintenance therapy was gradually restarted and she remained well at follow-up visits. Myelotoxicity from methotrexate and 6-mercaptopurine may represent an unpredictable incident during an otherwise uneventful maintenance therapy, and may occur independently of other organ toxicities.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Enfermedades de la Médula Ósea/inducido químicamente , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamiento farmacológico , Niño , Manejo de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Mercaptopurina/administración & dosificación , Metotrexato/administración & dosificación , Pronóstico
4.
J Rheumatol ; 40(1): 74-9, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23118110

RESUMEN

OBJECTIVE: To evaluate safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of juvenile idiopathic arthritis-related anterior uveitis (JIA-AU). METHODS: Starting January 2007, patients with JIA-AU treated with IFX and ADA were managed by a standard protocol and data were entered into the National Italian Registry (NIR). At baseline, all patients were refractory to standard immunosuppressive treatment and/or were corticosteroid-dependent. Data recorded every 3 months included uveitis course, number/type of ocular complications, drug-related adverse events (AE), treatment change or withdrawal, and laboratory measures. Data of patients treated for at least 1 year were retrieved from the NIR and analyzed using descriptive statistics. Treatment efficacy was based on change in uveitis course and in number of ocular complications. RESULTS: Up to December 2009, data for 108 patients with JIA-AU treated with anti-tumor necrosis factor-α agents were recorded in the NIR and data from 91, with at least 12 months' followup, were included in the study. Forty-eight patients were treated with IFX, 43 with ADA. Forty-seven patients (55.3%) achieved remission of AU, 28 (32.9%) had recurrent AU, and 10 (11.8%) maintained a chronic course. A higher remission rate was observed with ADA (67.4% vs 42.8% with IFX; p = 0.025). Ocular complications decreased from 0.47 to 0.32 per subject. Five patients experienced resolution of structural complications. No patient reported serious AE; 8 (8.8%) experienced 11 minor AE (9 with IFX, 2 with ADA). CONCLUSION: IFX and ADA appear to be effective and safe for treatment of refractory JIA-related uveitis, with a better performance of ADA in the medium-term period.


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Antirreumáticos/uso terapéutico , Artritis Juvenil/tratamiento farmacológico , Uveítis/tratamiento farmacológico , Adalimumab , Adolescente , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales Humanizados/efectos adversos , Antirreumáticos/efectos adversos , Artritis Juvenil/complicaciones , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Lactante , Infliximab , Italia , Masculino , Sistema de Registros , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Uveítis/complicaciones
5.
Ophthalmic Genet ; 31(2): 98-100, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20450314

RESUMEN

PURPOSE: Lymphedema-Distichiasis (LD, OMIM 153400) is an autosomal dominant disorder with variable expression. The mutated gene implicated is FOXC2, which encodes for a forkhead transcription factor involved in the development of the lymphatic and vascular system. LD is characterized by late childhood or pubertal onset lymphedema of the limbs and distichiasis. Other associations have been reported, including congenital heart disease, ptosis, scoliosis. CONCLUSIONS: Here we describe a case of LD carrying a de novo frameshift mutation of FOXC2 who presented a prepubertal onset of lower limbs lymphedema and mild distichiasis associated with other anomalies such as webbing neck and ptosis.


Asunto(s)
Anomalías del Ojo/genética , Pestañas/anomalías , Factores de Transcripción Forkhead/genética , Mutación del Sistema de Lectura , Linfedema/genética , Anomalías Múltiples/genética , Adolescente , Cara/anomalías , Humanos , Masculino , Síndrome
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...